G6PD and prostate carcinoma: Emerging research indicates that the pentose phosphate pathway (PPP), particularly through its rate-limiting enzyme glucose-6-phosphate dehydrogenase (G6PD), plays a critical role in the progression of prostate cancer to bone metastases, correlating with a poorer prognosis [14].